These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 25641431

  • 1. Possible implication of IKAROS gene deletion and BCR-ABL1 variants in progression of chronic myeloid leukemia to lymphoid blast crisis in childhood: a single-institution experience.
    Moschovi M, Adamaki M, Athanasiadou A, Divane A, Karytianou A, Tourkantoni N.
    Leuk Lymphoma; 2015; 56(8):2460-2. PubMed ID: 25641431
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.
    Haaß W, Kleiner H, Weiß C, Haferlach C, Schlegelberger B, Müller MC, Hehlmann R, Hofmann WK, Fabarius A, Seifarth W, Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung, German CML Study Group.
    PLoS One; 2015; 10(6):e0129648. PubMed ID: 26087013
    [Abstract] [Full Text] [Related]

  • 4. [Research advance on molecular genetics of CML blast crisis].
    Zhu HQ, Zhang S, Liu XL.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
    [Abstract] [Full Text] [Related]

  • 5. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV.
    Cancer Res; 2005 Oct 01; 65(19):8912-9. PubMed ID: 16204063
    [Abstract] [Full Text] [Related]

  • 6. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.
    Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, White D, Hughes TP, Le Beau MM, Pui CH, Relling MV, Shurtleff SA, Downing JR.
    Nature; 2008 May 01; 453(7191):110-4. PubMed ID: 18408710
    [Abstract] [Full Text] [Related]

  • 7. IKZF1 deletion and co-occurrence with other aberrations in a child with chronic myeloid leukemia progressing to acute lymphoblastic leukemia.
    Klumb CE, Barbosa TDC, Nestal de Moraes G, Schramm MT, Emerenciano M, Maia RC.
    Pediatr Blood Cancer; 2019 Apr 01; 66(4):e27570. PubMed ID: 30511400
    [Abstract] [Full Text] [Related]

  • 8. Acquisition of Inv(16)(p13q22) in a blast crisis of chronic myeloid leukemia: case report.
    Oñate G, Blanco ML, Pratcorona M.
    Med Clin (Barc); 2019 May 17; 152(10):419-420. PubMed ID: 30392698
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
    Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, Roy DC, Caligiuri MA, Bloomfield CD, Byrd JC, Perrotti D.
    J Clin Invest; 2007 Sep 17; 117(9):2408-21. PubMed ID: 17717597
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update.
    Bavaro L, Martelli M, Cavo M, Soverini S.
    Int J Mol Sci; 2019 Dec 05; 20(24):. PubMed ID: 31817512
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF, Moura LG, Tojal I, Ambrósio L, Pinto-Simões B, Hamerschlak N, Calin GA, Ivan C, Covas DT, Kashima S, Castro FA.
    Blood Cells Mol Dis; 2014 Dec 05; 53(1-2):47-55. PubMed ID: 24629639
    [Abstract] [Full Text] [Related]

  • 19. Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate.
    Aleem A, Siddiqui N.
    Leuk Lymphoma; 2005 Jul 05; 46(7):1097-9. PubMed ID: 16019565
    [Abstract] [Full Text] [Related]

  • 20. Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy.
    Proschmann R, Baldow C, Rothe T, Suttorp M, Thiede C, Tauer JT, Müller MC, Hochhaus A, Roeder I, Glauche I.
    Haematologica; 2017 Feb 05; 102(2):e39-e42. PubMed ID: 27856510
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.